The initial prospectus stated how the company growth was planned, and this included other drugs and other cancers.
The potential fast track approval pathway for Chlorotoxin is still the priority. With potentially just one trial required for FDA approval after the current phase 1 trial is finished, if results support this. If this approval is given, and its not that far away, I dont think there will be any problem financing other drugs and other trials.
So this prelaunch pitch seems pretty close to what is planned and happening.
CHM Price at posting:
26.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)